Patients with acute spontaneous coronary artery dissection (SCAD) are preferably managed conservatively given the good overall results shown with this approach1. In some cases, however, SCAD leads to compromised coronary flow, causing ongoing myocardial ischaemia and requiring revascularisation, generally by percutaneous coronary intervention (PCI)1. Bioresorbable vascular scaffolds (BVS) have emerged as an attractive option to avoid a permanent prosthesis and to allow vessel functional recovery in SCAD patients, who are generally young and have non-atherosclerotic arteries that tend to heal spontaneously1. However, first-generation BVS showed worse performance than benchmark drug-eluting stents2. Despite this, newer-generation BVS are expected to show improved outcomes in atherosclerotic patients and perhaps in SCAD patients2. We evaluated the long-term clinical outcomes of SCAD patients treated with first-generation BVS and provide data in this article to inform future decisions about platform choice.
Sign in to read and download the full articleForgot your password?
Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com